(Q45121900)

English

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

scientific article published in March 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

0 references

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis (English)

1 reference

Europe PubMed Central

9 December 2017

0 references

venous thromboembolism

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Siragusa S

1

1 reference

Europe PubMed Central

9 December 2017

Cosmi B

2

1 reference

Europe PubMed Central

9 December 2017

Piovella F

3

1 reference

Europe PubMed Central

9 December 2017

Hirsh J

4

1 reference

Europe PubMed Central

9 December 2017

Ginsberg JS

5

1 reference

Europe PubMed Central

9 December 2017

language of work or name

0 references

publication date

1 March 1996

1 reference

Europe PubMed Central

9 December 2017

American Journal of Medicine

1 reference

Europe PubMed Central

9 December 2017

100

1 reference

Europe PubMed Central

9 December 2017

3

1 reference

Europe PubMed Central

9 December 2017

269-277

1 reference

Europe PubMed Central

9 December 2017

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Effect of Heparin and Heparin Fractions on Platelet Aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Laboratory monitoring of the clinical effects of low molecular weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Low-molecular-weight heparin: is small beautiful?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Treatment of acute pulmonary embolism by a low molecular weight heparin fraction. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Publication bias in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Incorporating variations in the quality of individual randomized trials into meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2989484-3

7 January 2021

Identifiers

10.1016/S0002-9343(97)89484-3

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45121900&oldid=2066449195"